BOSTON (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Tuesday reported a loss of $23.5 million in its third quarter.
On a per-share basis, the Boston-based company said it had a loss of 20 cents.
The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.
The biopharmaceutical company posted revenue of $15 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $18.8 million.
Keryx Biopharma shares have increased slightly more than 6 percent since the beginning of the year. The stock has increased 35 percent in the last 12 months.